問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Radiation Therapy

Division of Otolaryngology

更新時間:2024-06-03

王仲祺Wang, Chen-Chi
  • Principal Investigator
  • Clinical Trial Experience (year)
  • entccwang@msn.com

篩選

List

17Cases

2022-01-31 - 2028-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2029-12-12

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2024-10-31 - 2029-02-28

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2018-01-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-11-30 - 2027-03-31

Phase I/II

Completed
Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
  • Condition/Disease

    Advanced Solid Tumor

  • Test Drug

    注射劑 注射液

Participate Sites
4Sites

Recruiting4Sites

2024-01-01 - 2027-07-31

Phase II

Completed
test
  • Condition/Disease

    test

  • Test Drug

    test

Participate Sites
6Sites

Recruiting6Sites

2020-08-14 - 2027-07-24

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-10-15 - 2024-06-13

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2019-01-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-01-31 - 2026-03-31

Phase III

A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC
  • Condition/Disease

    Locally Advanced Head and Neck Squamous Cell Carcinoma

  • Test Drug

    NBTXR3NBTXR3

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

1 2